Max Robotics — Global Service Robot Directory + US Certification

About

Masataka Amisaki is a prominent surgical oncologist whose research centers on advanced gastric cancer treatment and minimally invasive surgical techniques. His work has significantly advanced the understanding of both novel therapeutic combinations and perioperative outcomes. Dr. Amisaki’s major contributions include documenting the first real-world cases of protein-losing enteropathy induced by zolbetuximab, a CLDN18.2-targeted therapy, highlighting critical safety considerations for HER2-negative, CLDN18.2-positive unresectable advanced gastric cancer patients. This work, published in 2025, has already garnered 13 citations, underscoring its immediate clinical relevance. Additionally, his comparative analysis of robotic versus laparoscopic gastrectomy, with 10 citations, provides vital insights into perioperative performance and three-year survival outcomes, guiding surgical decision-making. Dr. Amisaki’s research bridges the gap between cutting-edge targeted therapies and surgical innovation, offering practical guidance for managing complex gastric cancer cases. His meticulous documentation of adverse events and surgical outcomes has established him as a key voice in optimizing treatment strategies, making his work essential reading for oncologists and surgeons seeking to improve patient care in this challenging field.